Indapamide may increase the hypercalcemic activities of Calcipotriol. Cortisone acetate may increase the hypokalemic activities of Indapamide. The risk or severity of adverse effects can be increased when Indapamide is combined with Eprosartan. Nialamide may increase the hypotensive activities of Indapamide. Fluticasone furoate may increase the hypokalemic activities of Indapamide. The serum concentration of Indapamide can be increased when it is combined with Propiverine. The metabolism of Indapamide can be decreased when combined with Clarithromycin. Indapamide may increase the QTc-prolonging activities of Quinine. Indapamide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level. The therapeutic efficacy of Indapamide can be decreased when used in combination with Niflumic Acid. The therapeutic efficacy of Indapamide can be decreased when used in combination with Carbaspirin calcium. The metabolism of Indapamide can be decreased when combined with Saquinavir. The therapeutic efficacy of Indapamide can be decreased when used in combination with Evening primrose oil. The risk or severity of adverse effects can be increased when Ramipril is combined with Indapamide. Indacaterol may increase the hypokalemic activities of Indapamide. The therapeutic efficacy of Gliclazide can be decreased when used in combination with Indapamide. Indapamide may increase the QTc-prolonging activities of Asenapine. The therapeutic efficacy of Glibornuride can be decreased when used in combination with Indapamide. The therapeutic efficacy of Glipizide can be decreased when used in combination with Indapamide. The serum concentration of Indapamide can be increased when it is combined with Stiripentol. The therapeutic efficacy of Buformin can be decreased when used in combination with Indapamide. The risk or severity of adverse effects can be increased when Esmolol is combined with Indapamide. The therapeutic efficacy of Indapamide can be decreased when used in combination with Propacetamol. Indapamide may increase the hypokalemic activities of Topiramate. The risk or severity of adverse effects can be increased when Diltiazem is combined with Indapamide. Indapamide may increase the QTc-prolonging activities of Nilotinib. The risk or severity of adverse effects can be increased when Indapamide is combined with Isosorbide Dinitrate. The serum concentration of Indapamide can be increased when it is combined with Trihexyphenidyl. Indapamide may increase the hypotensive activities of Rescinnamine. The therapeutic efficacy of Indapamide can be decreased when used in combination with Triptolide. The serum concentration of Indapamide can be increased when it is combined with Chlorphenoxamine. Arbutamine may increase the hypokalemic activities of Indapamide. The metabolism of Indapamide can be decreased when combined with Bortezomib. The therapeutic efficacy of Indapamide can be decreased when used in combination with Anisodamine. The risk or severity of adverse effects can be increased when Minoxidil is combined with Indapamide. The serum concentration of Indapamide can be increased when it is combined with Dasatinib. The therapeutic efficacy of Alogliptin can be decreased when used in combination with Indapamide. The risk or severity of adverse effects can be increased when Clomipramine is combined with Indapamide. Indapamide may increase the QTc-prolonging activities of Chlorpromazine. The therapeutic efficacy of Liraglutide can be decreased when used in combination with Indapamide. The serum concentration of Indapamide can be increased when it is combined with Netupitant. Travoprost may increase the hypotensive activities of Indapamide. The risk or severity of adverse effects can be increased when Indapamide is combined with Papaverine. Indapamide may increase the QTc-prolonging activities of Crizotinib. Rilmenidine may increase the hypotensive activities of Indapamide. The risk or severity of adverse effects can be increased when Methadone is combined with Indapamide. Dobutamine may increase the hypokalemic activities of Indapamide. The risk or severity of adverse effects can be increased when Levorphanol is combined with Indapamide. The therapeutic efficacy of Indapamide can be decreased when used in combination with Droxicam. The therapeutic efficacy of Indapamide can be decreased when used in combination with Ibuprofen. The risk or severity of adverse effects can be increased when Isradipine is combined with Indapamide. Indapamide may increase the QTc-prolonging activities of Promazine. Moclobemide may increase the hypotensive activities of Indapamide. The serum concentration of Indapamide can be increased when it is combined with Dicyclomine. Indapamide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level. The therapeutic efficacy of Indapamide can be decreased when used in combination with Chloroquine. The risk or severity of adverse effects can be increased when Indapamide is combined with Nadolol. Formestane may increase the hypokalemic activities of Indapamide. The risk or severity of adverse effects can be increased when Nimodipine is combined with Indapamide. The therapeutic efficacy of Indapamide can be decreased when used in combination with Serrapeptase. Indapamide may increase the QTc-prolonging activities of Pazopanib. The metabolism of Indapamide can be increased when combined with Fosphenytoin. The therapeutic efficacy of Insulin Human can be decreased when used in combination with Indapamide. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Indapamide. Pheniprazine may increase the hypotensive activities of Indapamide. The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Indapamide. Hydracarbazine may increase the hypotensive activities of Indapamide. The therapeutic efficacy of Indapamide can be decreased when used in combination with Ketorolac. The risk or severity of adverse effects can be increased when Spironolactone is combined with Indapamide. The serum concentration of Indapamide can be increased when it is combined with Propantheline. The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Indapamide. The metabolism of Indapamide can be decreased when combined with Fosamprenavir. Indalpine may increase the hyponatremic activities of Indapamide. The therapeutic efficacy of Indapamide can be decreased when used in combination with Carprofen. Tolazoline may increase the hypotensive activities of Indapamide. The therapeutic efficacy of Indapamide can be decreased when used in combination with Seratrodast. Fluprednidene may increase the hypokalemic activities of Indapamide. The therapeutic efficacy of Indapamide can be decreased when used in combination with Leflunomide. Fludrocortisone may increase the hypokalemic activities of Indapamide. The risk or severity of adverse effects can be increased when Ropinirole is combined with Indapamide. Indapamide may increase the QTc-prolonging activities of Leuprolide. The risk or severity of adverse effects can be increased when Indapamide is combined with Acetyldigitoxin. The therapeutic efficacy of Indapamide can be decreased when used in combination with Mesalazine. Indapamide may increase the hypotensive activities of Spirapril. The therapeutic efficacy of Indapamide can be decreased when used in combination with Semapimod. Indapamide may increase the hypotensive activities of Xylometazoline. The risk or severity of adverse effects can be increased when Imidapril is combined with Indapamide. The risk or severity of adverse effects can be increased when Doxazosin is combined with Indapamide. The serum concentration of Indapamide can be decreased when it is combined with St. John's Wort. Terbutaline may increase the hypokalemic activities of Indapamide. The risk or severity of adverse effects can be increased when Tolcapone is combined with Indapamide. The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Indapamide. Indapamide may increase the hypotensive activities of Saprisartan. Fenoldopam may increase the hypotensive activities of Indapamide. Indapamide may increase the QTc-prolonging activities of Thioridazine. The serum concentration of Indapamide can be increased when it is combined with Aprepitant. Indapamide may increase the arrhythmogenic activities of Ivabradine. The risk or severity of adverse effects can be increased when Bisoprolol is combined with Indapamide. The therapeutic efficacy of Indapamide can be decreased when used in combination with Benzydamine. The risk or severity of adverse effects can be increased when Indapamide is combined with Etacrynic acid. Hydrocortisone may increase the hypokalemic activities of Indapamide. The risk or severity of adverse effects can be increased when Rotigotine is combined with Indapamide. The serum concentration of Indapamide can be decreased when it is combined with Vemurafenib. The risk or severity of adverse effects can be increased when Perindopril is combined with Indapamide. The risk or severity of adverse effects can be increased when Indapamide is combined with Azilsartan medoxomil. Indapamide may increase the hypotensive activities of Enalaprilat. Indapamide may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level. Levosalbutamol may increase the hypokalemic activities of Indapamide. The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Indapamide. The therapeutic efficacy of Indapamide can be decreased when used in combination with Rofecoxib. Estrone may increase the hypokalemic activities of Indapamide. The serum concentration of Indapamide can be increased when it is combined with Pancuronium. The risk or severity of adverse effects can be increased when Indapamide is combined with Felodipine. Indapamide may increase the hypotensive activities of Manidipine. The risk or severity of adverse effects can be increased when Clonidine is combined with Indapamide. The risk or severity of adverse effects can be increased when Tramadol is combined with Indapamide. Indapamide may increase the QTc-prolonging activities of Fluoxetine. The serum concentration of Indapamide can be increased when it is combined with Butylscopolamine. Clenbuterol may increase the hypokalemic activities of Indapamide. The metabolism of Indapamide can be decreased when combined with Doxycycline. Indapamide may increase the hypotensive activities of Dorzolamide. Phenelzine may increase the hypotensive activities of Indapamide. Clocortolone may increase the hypokalemic activities of Indapamide. Amobarbital may increase the orthostatic hypotensive activities of Indapamide. The metabolism of Indapamide can be decreased when combined with Nefazodone. Isoprenaline may increase the hypokalemic activities of Indapamide. The risk or severity of adverse effects can be increased when Timolol is combined with Indapamide. Indapamide may increase the QTc-prolonging activities of Ibutilide. Anecortave may increase the hypokalemic activities of Indapamide. Indapamide may increase the QTc-prolonging activities of Telavancin.